(Q46472600)

English

Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence

scientific article published in September 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

David R Bangsberg

5

object named as

David R Bangsberg

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

1

object named as

Sheri D Weiser

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

author name string

David Guzman

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

Elise D Riley

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

Richard Clark

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

278-287

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Factors affecting adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

1 reference

https://api.crossref.org/works/10.1310%2FLNHD-K1R7-HQP5-HJCQ

21 January 2018

Identifiers

10.1310/LNHD-K1R7-HQP5-HJCQ

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15562368

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46472600&oldid=2113200381"